AllDocs -> cancers

What you need to know about ProstateCancer The Institute of Cancer Research 123 Old Brompton Road London SW7 3RP Tel: 020 7153 5000 Fax: 020 7153 5313 Web: www.icr.ac.uk The Institute of Cancer Research: Royal Cancer Hospital. Registered Office, as above. A Charity, Not for Profit. Company limited by Guarantee. Registered in England No. 534147. Page 2 What is Prostate Cancer ? The prostate is a male sex gland located underneath the bladder. It is about the size of a walnut and fits around the tube (the urethra) which carries urine out of the bladder. The prostate produces a thick fluid that forms part of the semen. Approximately 30,000 men are diagnosed with prostate cancer each year. It is has now overtaken lung cancer to become the UK’s most commonly diagnosed cancer ...

CANCER THERAPEUTICS/ CANCER BIOLOGY 51 Chris Parker MD MRCP FRCR Chris Parker is a Cancer Research UK Clinician Scientist in the Section of Academic Radiotherapy at The Institute of Cancer Research and Honorary Consultant in the Department of Radiotherapy at The Royal Marsden NHS Foundation Trust Prostate cancer : Occurrence and risk • Prostate cancer is the most common cancer in UK men, with 30,000 new cases diagnosed each year. • As many as 80% of men develop prostate cancer during their lifetime, but in most cases it does not cause any ill health. Around 6% of men experience symptoms of the disease, while 3% of men die of prostate cancer . • Screening for prostate cancer using the Prostate Specific Antigen (PSA) blood test remains very controversial but, for better or worse, ...

RADIO THERAPY – UROLOGIC AL C ANCERS 36 Main head 27 characters Sub Head 37 characters Name Name qualifications Professor of Breast Cancer Pathology and Consultant Histopathologist Detecting early stage prostate cancer — why is it a problem? T he apparent incidence of prostate cancer in the United States has more than doubled since the prostate specific antigen (PSA) blood test was introduced (Figure 1). This startling rise is consistent with the possibility that most cases detected by PSA screening are overdiagnosed – that is, even without any treatment, most patients would never have developed symptoms from their prostate cancer . However, prostate cancer is by no means uniformly slow growing, and it is responsible for 3% of all male deaths in the US. ...

CANCER BIOLOGY/RADIOTHERAPY Why is prostate cancer different? Prostate cancer poses a unique set of challenges for the laboratory scientist and clinician.As a result of prostate specific antigen (PSA) testing, prostate cancer has now become the most commonly diagnosed male cancer in the western world with over 27,000 cases recorded annually in the UK. It remains a major cause of mortality with nearly 10,000 cancer deaths per year.Yet, paradoxically most of the early prostate cancer now diagnosed by PSA testing may not need treating at all.The rate of progression is frequently so slow that the disease is of no threat – indeed autopsy studies show microfocal invasive disease in about 80% of 80-year-old men. There is a pressing need to understand the processes that lead to disease progression in prostate cancer and to determine the ...

Circulating Biomarkers of Prostate Cancer This project will generate methods to assess an individual's risk of developing prostate cancer and characterizing the nature of the local tumor using early molecular and cellular signatures resulting from transformation of normal prostate epithelium to invasive prostate cancer . Our program will address the major and urgent challenge in translating emerging cutting-edge developments into clinical practiceOur efforts will address current limitations in assessing an individual's risk of developing prostate cancer and characterizing the nature of the local tumor and its need for immediate treatment. This will be accomplished by addressing the following issues: 1. Measure recently identified, novel circulating biomarkers in blood samples from population- based studies to assess risk of developing clinically significant prostate cancer years before it is ...

Prostate cancer testing The prostate is a small walnut-shaped gland found only in men. It surrounds the urethra, which is the tube through which urine passes from the bladder to the penis. As men get older, the prostate may become larger. This benign growth can squeeze the urethra and cause men to have difficulties urinating. Problems with urinating are common in men over 50 In Victoria, about one in three men over 50 have problems with urinating. These problems include: • Difficulty starting • Slow stream • Urinating more frequently than usual, especially at night • Dribbling of urine after urinating • Pain or a burning feeling when urinating • Appearance of blood in the urine. If you have any of these symptoms, particularly blood in the urine, see your doctor. They are not necessarily signs of prostate cancer . They are most ...

Prostate cancer and the PSA test Prostate cancer affects one in 18 Australian males and is common in men over the age of 65 years. Prostate cancer is diagnosed using a range of tests, including the PSA blood test. A normal prostate secretes a protein into the ejaculate called prostate specific antigen (PSA). This protein helps to nourish sperm in the ejaculate, and only tiny amounts of PSA leech into the bloodstream. However, cancer cells in the prostate interfere with proper functioning and cause large amounts of PSA to enter the blood. In around one in three cases, a high PSA level is caused by cancer . Another common cause of elevated PSA is a prostate condition called benign prostatic enlargement. For this reason, the PSA blood test isn’t used in isolation when checking for prostate cancer . Tests such as a tissue biopsy are needed to confirm the ...

Prostate Cancer Page 2 What causes prostate cancer ? No one knows for sure what causes prostate cancer . Advancing age seems to be a factor. Prostate cancer usually starts to appear in men after age 55, and the average age at diagnosis is 70. If a man’s father or brother has a history of prostate cancer , he is at increased risk to develop the disease. Prostate cancer is more common in African Americans, and less common in men of Asian or Native American ancestry. Some evidence suggests that a diet high in fat may be a contributing factor. Conversely, a diet rich in fruits and vegetables seems to have a protective effect. How is prostate cancer diagnosed? During a physical examination, your doctor will perform a digital-rectal examination (DRE), where the gloved finger is used to feel the prostate gland through the wall ...

The pros and cons of PSA screening for prostate cancer A screening test for prostate cancer has been available for some years.It is known as the PSA test and is a blood test. There is some debate at the moment on the benefits of using this test in men who show no signs of cancer . The reason for the controversy is that the PSA test does not yet meet the generally accepted criteria for a screening test. However, we know that the PSA test is the best way to detect prostate cancer at an early stage of the disease,when there is a good chance of cure. This pamphlet is designed to give you the information you need to discuss prostate cancer screening with your doctor before making your own decision. The Pros and Cons of PSA SCREENING for PROSTATE CANCER If you are a man aged 45-75 years ...

Bowel and Prostate Cancer Wednesday 6September 2006 7:30 pm – 9:30 pm Chelsea Heights Beazley Reserve 160 Thames Promenade Chelsea Heights 3196 Mel ref: 93 F12 Seat bookings are essential. For further information and bookings call: 13 11 20 RSVP 4 th September 2006 Proudly supported by: Speakers will present latest information on bowel and prostate cancer . Mr.Chris Chang - Urologist (MBBS.FRACS) Mr. Ross Ferguson – General Surgeon (MBBS.DIP.ANAT.FRACS) Heather Widjaja – The Cancer Council Victoria Cancer Education Unit Following the speakers, there will be an opportunity to ask questions in a relaxed environment. A light supper will follow. Men and women, family and friends are all welcome to attend.

What Men Need To Know about Prostate Cancer and PSA Prostate cancer is the second most commonly diagnosed type of cancer in men, with lung cancer being the first. Luckily, prostate cancer also happens to be a type of cancer that responds extremely well to alternative cancer treatments. For example, the Protocel formula is one approach with a history of working remarkably well for prostate cancer . Flaxseed Oil and Cottage Cheese, ellagic acid (or ellagitannin supplements), Cesium High pH Therapy and herbal formulas such as Essiac have also produced complete recoveries for men with prostate cancer . Thus, little effort is required to find great cases of complete prostate cancer recoveries among men using alternative non-toxic methods. On the other hand, conventional (or mainstream) medicine has NOT had significant success treating prostate cancer , especially once the cancer ...

Mandatory Coverage * Oklahoma law requires specified insurers to offer coverage for prostate cancer screening. * Fact Sheet: Prostate Cancer Screening States with Laws Related to Third-Party Coverage by Private Insurers for Prostate Cancer Screening (as of September 30,2005) State Cancer Legislative Database Program, NCI Source: National Cancer Institute: State Cancer Legislative Database Program,Bethesda,MD,2005 Building 31, Room 10A48 • 31 Center Drive, MSC 2580 • Bethesda, Maryland 20892-2580 • 301 496 5217 • 301 402 1225 fax • http://www.scld-nci.net N atioNal C aNCer i Nstitute · s tate C aNCer l egislative D atabase P rogram o Ctober 2005 The SCLD contains information synthesized from ...

Fox Chase Cancer Center 2005 Scientific Report 1 Prostate cancer detection in a high-risk population. Bruner, Konski, Feigenberg, Uzzo, Giri, Bower, Raysor, in collaboration with Hanks, a Mirchandani, b Greenberg, § Pollack § Black men with a family history of prostate cancer diagnosed at younger age than white men with similar family history. African-American (AA) males and Caucasian males with a family his- tory of prostate cancer (PCA) have been shown to be at increased risk of developing prostate cancer . We report the results of the first 520 males enrolled in the Prostate Cancer Risk Assessment Program, a high-risk prostate cancer screening program. AA men and Caucasian men with at least one first-degree or = 2 second degree relatives diagnosed with ...

EFFECTIVENESS EFFECTIVENESS Matters Matters NHS CENTRE FOR REVIEWS AND DISSEMINATION Effectiveness Matters is an update on the effectiveness of health interventions for practitioners and decision makers in the NHS. It is produced by researchers at the NHS Centre for Reviews and Dissemination at the University of York, based on high quality systematic reviews of the research evidence. Effectiveness Matters is extensively peer reviewed by subject area experts and practitioners. The NHS Centre for Reviews and Dissemination is funded by the NHS Executive and the Health Departments of Scotland, Wales and Northern Ireland; a contribution to the Centre is also made by the University of York. The views expressed in this publication are those of the authors and not necessarily those of the NHS Executive or the Health Departments of Scotland, Wales or Northern Ireland. ...

more Media Contacts Simi Singer – Cedars-Sinai Keith Andre - Centinela E-mail: simi.singer@cshs.org Keith.Andre@centinelafreeman.com Telephone: 310-423-7798 Telephone: 310-674-7050 PROSTATE CANCER PATIENTS SOUGHT FOR DATABASE AS PART OF JOINT EFFORT AT CEDARS-SINAI MEDICAL CENTER AND CENTINELA FREEMAN REGIONAL MEDICAL CENTER IN INGLEWOOD Researchers at both medical centers hope data will help them understand the biology of prostate cancer and lead to the development of future treatments. (LOS ANGELES, CA) August 11, 2006 – Men with prostate cancer and their spouses/significant others are being sought for a joint study being conducted by two Los Angeles-area medical centers as part of a collaborative effort to better understand the genetics of the disease. Prostate cancer is the most common form of cancer in men. Cedars-Sinai Medical ...

Prostate Cancer Prostate cancer is the most common cancer among American men. In fact, one in six men will hear the words “you have prostate cancer ” in his lifetime. WarnInG sIGns Most prostate cancer has no symptoms. Some men with prostate cancer have problems urinating, but this problem can also be caused by something less serious. Only a doctor can know for sure. rIsK faCTors • The risk of prostate cancer goes up with age. Over 90 percent of cases are diagnosed in men over the age of 55. • Men who have a father or brother with prostate cancer have a higher risk of the disease. The younger and closer the relative, the higher the risk. • African-American men have the highest rates of prostate cancer in the world. PrevenTIon | loWerYour rIsK There have been a variety of studies looking at potential ...

Health on Update Page 2 Behind the Numbers What do your blood pressure and cholesterol numbers mean? Page 3 New Women’s Imaging Center Opening This Month The Patient Newsletter fromThe Austin Diagnostic Clinic Vol I, Issue 2 Prostate cancer is often thought of as a male disease. But since women are two times as likely as men to see their physicians for annual exams, it is up to mothers, wives, sisters and daughters to encourage the men in their lives to take control of their health. So what should every woman know about prostate cancer ? The prostate is a walnut-sized gland that is part of the male reproductive system. It surrounds the urethra, the canal that carries urine from the bladder out of the body, and secretes fluid that transports sperm. Prostate cancer is the second leading ...

September – Prostate Cancer Awareness Month SYMPTOMS The following problems may be symptoms of prostate cancer or could be caused by infections, prostate enlargement, or other prostate conditions and should by evaluated by a physician: • Difficulty starting to urinate • Less force to the urine stream or dribbling after finishing urinating • Frequent urination • Blood or pus in the urine • Pain or burning feeling while urinating • Pain with ejaculation • Hip or back pain that does not go away RISK FACTORS • Age: Prostate cancer is found most often in men older than age 50; 64% of Michigan men diagnosed with prostate cancer in 2001 and 94% of deaths from prostate cancer in 2002 were in men 65 years of age or older. • African Ancestry: Black men are affected disproportionately by prostate ...

PROSTATE CANCER SYMPTOMS The following problems may be symptoms of prostate cancer or could be caused by infections, prostate enlargement, or other prostate conditions and should by evaluated by a physician: • Difficulty starting to urinate • Less force to the urine stream or dribbling after finishing urinating • Frequent urination • Blood or pus in the urine • Pain or burning feeling while urinating • Pain with ejaculation • Hip or back pain that does not go away RISK FACTORS • Age: Prostate cancer is found most often in men older than age 50; 64% of Michigan men diagnosed with prostate cancer in 2001 and 94% of deaths from prostate cancer in 2002 were in men 65 years of age or older. • African Ancestry: Black men are affected disproportionately by prostate cancer . The diagnosis ...

RACIAL DIFFERENCES IN PROSTATE CANCER : INFLUENCE OF HEALTH CARE INTERACTION AND HOST AND TUMOR BIOLOGY PUBLIC ABSTRACT James L. Mohler, M.D., Consortium Director Background Prostate cancer is the most common cancer in men and the second leading cause of cancer mortality. In men younger than 65 years of age, the prostate cancer mortality rate for African Americans is 3.1 times that of Caucasian Americans. In men 65 years of age and older, the prostate cancer mortality rate for African Americans is 2.3 times that of Caucasian Americans. Three potential reasons have been suggested frequently to explain the disproportionate mortality from prostate cancer in African Americans compared to Caucasian Americans. First, African Americans present more often with advanced, incurable prostate cancer because of more limited access to health care due to socioeconomic status resulting in decreased ...

Technical Abstract Mohler, James L. RACIAL DIFFERENCES IN PROSTATE CANCER : INFLUENCE OF HEALTH CARE INTERACTION AND HOST AND TUMOR BIOLOGY TECHNICAL ABSTRACT James L. Mohler M.D., Consortium Director Background Prostate cancer is the most common cancer in men and the second leading cause of cancer mortality. In men younger than 65 years of age, the prostate cancer mortality rate for African Americans is 3.1 times that of Caucasian Americans. In men 65 years of age and older, the prostate cancer mortality rate for African Americans is 2.3 times that of Caucasian Americans. Three potential reasons have been suggested frequently to explain the disproportionate mortality from prostate cancer in African Americans compared to Caucasian Americans. First, African Americans present more often with advanced, incurable prostate cancer because of more limited access to health ...

Racial differences in lifestyle modification in men with CaP Dr. Jessie Satia, PI Racial Differences in Lifestyle Modification in Men with Newly-Diagnosed Prostate Cancer T ECHNICAL A BSTRACT Background: Prostate cancer is the most common cancer in men and the second leading cause of cancer mortality. African Americans have the highest prostate cancer incidence and mortality rates among all racial/ethnic groups; prostate cancer mortality in African Americans is 2.3 times that of Caucasian Americans. Further, recurrence rates for prostate cancer after definitive treatment have been shown to be significantly higher in African Americans, and black race has been associated with decreased survival. Research suggests that prostate cancer prognosis may be affected by lifestyle factors: prostate cancer may be particularly impacted by ...

- 1 - Created on 8/1/2006 2:10:00 PM 2006 PROGRAM IN PROSTATE CANCER RESEARCH/SPORE MEETINGS 5:00-6:00 PM PPCR SEMINARS SPEAKER TITLE SEMINAR LOCATION DAYTIME MEETING LOCATION JANUARY 19, 2006 Michael Freeman, Ph.D., Harvard Medical School, Children’s Hospital Boston, Department: Urology, David E. Retik Director of Basic Urologic Research, Associate Professor of Surgery. “Signaling Complexes in Cholesterol-rich Membranes” FHCRC Thomas Bldg., Pelton Auditorium Feb 16, 2006 MEETING CANCELLED _ MARCH 16, 2006 Robert H. Getzenberg, Ph.D. Director of Urology Research, Brady Urological Institute, Professor of Urology and Oncology Johns Hopkins Hospital “Novel Prostate Cancer Biomarkers Identified by Proteomic Analysis of Nuclear Structure.” FHCRC Thomas ...

Prostate Cancer Program A Commitment to Excellence One out of every six men in the United States will get prostate cancer . It is the second leading cause of cancer deaths in men. Tomasz Beer, M.D., and the Prostate Cancer Program at the OHSU Cancer Institute are out to change that. In a few short years, Dr. Beer has developed one of the most robust prostate cancer programs in the country. He and his colleagues have made groundbreaking discoveries that have improved the care of patients for all stages of prostate cancer . This highly respected, multi-disciplinary team has created a program that conducts clinical trials targeting every state of the disease – from risk reduction and prevention to treatment of early and advanced prostate cancer . The program is committed to transforming new discoveries into better ways to heal patients and save lives. The Prostate Cancer Program ...

The Manitoba Prostate Cancer Support Group Vol. : 166 - April 2005 The Manitoba Prostate Cancer Support Group encourages wives, loved ones, and friends to attend all meetings. Feel free to ask basic or personal questions without fear of embarrassment. You need not give out your name or other personal information. The Manitoba Prostate Cancer Support Group does not recommend treatment modalities, medications, or physicians. All information is however freely shared. Want to reach us by email ? manpros@mts . net Medical Advisors to The Manitoba Prostate Cancer Support Group J. Butler M.D. Radiation Oncologist Paul Daeninck M.D. Pain Management Graham Glezerson M.D. Urologist Alan Katz M.D. Family Practitioner Len Leboldus M.D. Urologist ...

prostate cancer Consultation: Experiences of Prostate Cancer in the South West Where do you live in the South West? Age: Brief description of your treatment: Where are/were you treated for your prostate cancer ? What do you think is good about prostate cancer services and treatment in your area? Please turn over What do you think ...

© 20 06 T HE AUT HO RS JOURNAL COMPI LA TI ON © 2 00 6 B J U I N TE RNA TI O NAL | 97 , 11 49 – 1153 | doi:10.1111/j.1464-410X.2006.06198.x 11 49 INTERFERING WITH CELL-SURVIVAL SIGNALLING AS A TREATMENT FOR PROSTATE CANCER CORCORAN et al. Interfering with cell-survival signalling as a treatment strategy for prostate cancer NIALL M. CORCORAN, ANTHONY J. COSTELLO and CHRISTOPHER M. HOVENS Departments of Urology and Surgery, University of Melbourne, Royal Melbourne Hospital, Parkville, Victoria, Australia Accepted for publication 7 February 2006 KEYWORDS prostate , prostatic malignancy, cell survival, apoptosis, signalling INTRODUCTION A mounting body of evidence implicates dysregulation of cell-survival signalling pathways in the pathogenesis of hormone- refractory prostate ...

What are the facts on Prostate Cancer ? Garvan Institute of Medical Research What is prostate cancer ? The prostate is a walnut- sized gland located immediately beneath the bladder and surrounding the urethra. It is found only in men, with its main function being the production of some of the seminal fluid that nourishes sperm. In normal situations, prostate cells divide under the control of hormones, maintaining the size and functions of the gland. In abnormal situations, this cell division process is uncontrolled, causing a build up of constantly replicating cells. If these cells continue to build up and extend into neighbouring tissues or organs, or move to other parts of the body, then the abnormal condition becomes prostate cancer . Most prostate cancers are very slow- developing and neither the patient nor doctor may ever notice any sign of ...

Disclaimer This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. Page 1 of 3 Related Change Request (CR) #: 3775 MLN Matters Number: MM3775 Related CR Release Date: July 22, 2005 Related CR Transmittal #: 612 Effective Date: March 15, 2005 Implementation Date: May 25, 2005 Abarelix for the Treatment of Prostate Cancer Note: This article was revised to contain Web addresses that conform to the new CMS web site and to ...

Providing access to the latest information on health-related funding opportunities Prostate Cancer 20 July 2006 Page 2 Each issue contains the following information for each funding body: • The contact name and phone number of the charity or funding organisation. • The aim of the organisation with reference to research funding. • The name of the award or calls for funding. • The contact details for the individual award, if it is different from the main contact details of the organisation. • The amount of funding available. • Specific aims of the individual grant • Any restriction(s) which apply to the grant. The details shown in this special edition is a sub-set of the information contained in the main RDFunding database, which can be viewed from the website www.rdfunding.org.uk. RDInfo (www.rdinfo.org.uk) is responsible for a trio of information services which ...